文献速递消化系统肿瘤

ABC-06:二线FOLFOX对比主动症状控制治疗晚期胆道癌的III期随机对照试验

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2021-03-30

ABC-06是在英国20个中心开展的III期开放标签随机对照试验,纳入162例一线顺铂+吉西他滨进展的晚期胆道癌患者,1:1随机接受主动症状控制(ASC)联合FOLFOX或单纯ASC。

要点

  • FOLFOX组3-5级不良事件更常见(69% vs 52%),包括3例化疗相关死亡。

核心结论

  • 对于一线顺铂+吉西他滨进展的晚期胆道癌患者,二线FOLFOX联合ASC较单纯ASC显著延长中位总生存期,且6个月和12个月总生存率有临床意义的提高。
  • 基于该研究结果,FOLFOX应成为晚期胆道癌二线治疗的标准化疗方案,并作为后续临床试验的参照方案。

研究设计与样本

  • ABC-06是一项在英国20个胆道癌诊疗中心开展的III期、开放标签、随机对照试验。
  • 纳入162例组织学或细胞学证实为局部晚期或转移性胆道癌(包括胆管癌、胆囊癌或壶腹部癌)、一线顺铂+吉西他滨化疗后影像学进展、ECOG体能状态0-1的成人患者(≥18岁)。
  • 患者1:1中央随机分配至ASC联合FOLFOX组(n=81)或单纯ASC组(n=81),随机化采用最小化算法,以铂类敏感性、血清白蛋白浓度和分期为分层因素。
  • FOLFOX方案为每2周静脉给药,最多12个周期:奥沙利铂85 mg/m2、L-亚叶酸175 mg(或亚叶酸350 mg)、氟尿嘧啶400 mg/m2(推注)及氟尿嘧啶2400 mg/m2持续46小时静脉输注。
  • 主要终点为意向治疗人群的总生存期,安全性同样在意向治疗人群中评估。

主要发现

  • 3-5级不良事件在单纯ASC组81例中42例(52%)报告,在联合组81例中56例(69%)报告,包括3例化疗相关死亡(分别死于感染、急性肾损伤和发热性中性粒细胞减少)。
  • FOLFOX相关最常见的3-5级不良事件为中性粒细胞减少(10例,12%)、乏力或嗜睡(9例,11%)和感染(8例,10%)。

关键数值与推荐

  • FOLFOX组3-5级不良事件发生率69%(56/81),单纯ASC组52%(42/81)。

临床怎么用

  • 对于一线顺铂+吉西他滨治疗后进展、ECOG PS 0-1的晚期胆道癌患者,可考虑二线FOLFOX化疗联合主动症状控制。
  • FOLFOX应作为晚期胆道癌二线治疗的标准方案,并作为后续临床试验的对照参照。

局限性

  • 研究为开放标签设计,未设盲。
  • 研究仅在英国开展,人群代表性可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine the benefit derived from second-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy in advanced biliary tract cancer. METHODS: The ABC-06 clinical trial was a phase 3, open-label, randomised trial done in 20 sites with expertise in managing biliary tract cancer across the UK. Adult patients (aged ≥18 years) who had histologically or cytologically verified locally advanced or metastatic biliary tract cancer (including cholangiocarcinoma and gallbladder or ampullary carcinoma) with documented radiological disease progression to first-line cisplatin and gemcitabine chemotherapy and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (1:1) centrally to active symptom control (ASC) and FOLFOX or ASC alone. FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m2, L-folinic acid 175 mg [or folinic acid 350 mg], fluorouracil 400 mg/m2 [bolus], and fluorouracil 2400 mg/m2 as a 46-h continuous intravenous infusion). Randomisation was done following a minimisation algorithm using platinum sensitivity, serum albumin concentration, and stage as stratification factors. The primary endpoint was overall survival, assessed in the intention-to-treat population. Safety was also assessed in the intention-to-treat population. The study is complete and the final results are reported. This trial is registered with ClinicalTrials.gov, NCT01926236, and EudraCT, 2013-001812-30. FINDINGS: Between March 27, 2014, and Jan 4, 2018, 162 patients were enrolled and randomly assigned to ASC plus FOLFOX (n=81) or ASC alone (n=81). Median follow-up was 21·7 months (IQR 17·2-30·8). Overall survival was significantly longer in the ASC plus FOLFOX group than in the ASC alone group, with a median overall survival of 6·2 months (95% CI 5·4-7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1-5·8) in the ASC alone group (adjusted hazard ratio 0·69 [95% CI 0·50-0·97]; p=0·031). The overall survival rate in the ASC alone group was 35·5% (95% CI 25·2-46·0) at 6 months and 11·4% (5·6-19·5) at 12 months, compared with 50·6% (39·3-60·9) at 6 months and 25·9% (17·0-35·8) at 12 months in the ASC plus FOLFOX group. Grade 3-5 adverse events were reported in 42 (52%) of 81 patients in the ASC alone group and 56 (69%) of 81 patients in the ASC plus FOLFOX group, including three chemotherapy-related deaths (one each due to infection, acute kidney injury, and febrile neutropenia). The most frequently reported grade 3-5 FOLFOX-related adverse events were neutropenia (ten [12%] patients), fatigue or lethargy (nine [11%] patients), and infection (eight [10%] patients). INTERPRETATION: The addition of FOLFOX to ASC improved median overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, with a clinically meaningful increase in 6-month and 12-month overall survival rates. To our knowledge, this trial is the first prospective, randomised study providing reliable, high-quality evidence to allow an informed discussion with patients of the potential benefits and risks from second-line FOLFOX chemotherapy in advanced biliary tract cancer. Based on these findings, FOLFOX should become standard-of-care chemotherapy in second-line treatment for advanced biliary tract cancer and the reference regimen for further clinical trials. FUNDING: Cancer Research UK, StandUpToCancer, AMMF (The UK Cholangiocarcinoma Charity), and The Christie Charity, with additional funding from The Cholangiocarcinoma Foundation and the Conquer Cancer Foundation Young Investigator Award for translational research.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021. PMID: 33798493. doi:10.1016/S1470-2045(21)00027-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。